Pharmacology and therapeutic efficacy of capecitabine: Focus on breast and colorectal cancer

Anti-Cancer Drugs

Volumn 20, Issue 4, 2009, Pages 217-229

  Aprile, Giuseppe ^a   Mazzer, Micol ^a   Moroso, Stefano ^a   Puglisi, Fabio ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Breast cancer; Capecitabine; Colorectal cancer; Pharmacology; Randomized clinical trials; Thymidine phosphorylase

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; IXABEPILONE; LAPATINIB; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PHENYTOIN; PLACEBO; PRODRUG; SORIVUDINE; THYMIDINE PHOSPHORYLASE; TRASTUZUMAB; WARFARIN;

ABDOMINAL DISCOMFORT; ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARDIOMYOPATHY; CARDIOTOXICITY; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY SPASM; DEHYDRATION; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DRUG ABSORPTION; DRUG ACTIVATION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME INDUCTION; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; INTESTINE PERFORATION; ISCHEMIA; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MALABSORPTION; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VOMITING; WOUND HEALING IMPAIRMENT;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; FEMALE; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; PRODRUGS;

EID: 63449129064     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283293fd4     Document Type: Review

References (131)

1. Testa B. Prodrug research: futile or fertile? Biochem Pharmacol 2004; 68:2097-2106.
2. McGavin JK, Goa KL Capecitabine: a review of its use in the treatment of advanced breast or metastatic colorectal cancer. Drugs 2001; 61.2309-2326.
3. Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist 2007; 12:375-389.
4. Cornelia P, Casaretti R, Sandomenico C, Avallone A, Franco L Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence. Drugs 2008; 68.949-961.
5. Dooley M, Goa KL Capecitabine. Drugs 1999; 58:69-76.
6. Miwa M, Ura M, Nishida M. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
7. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55:1091-1097.
8. Sobrero A, Guglielmi A, Grossi F, Puglisi F, Aschele C. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 2000; 27:72-77.
9. Budman DR, Meropol NJ, Reigner B, Cravean PJ, Lichtman SM, Berghorn E, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998; 16:1795-1802.
10. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, ef al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16:2977-2985.
11. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40:85-104.
12. Judson IR, Beale PJ, Trigo JM, Aherne W, Crompton T, Jones D, ef al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labeiled drug. Invest New Drugs 1999; 17:49-56.
13. Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J, ef al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49:225-234.
14. Twelves C, Glynne-Jones R, Cassidy J, Schuller J, Goggin T, Roos B, ef al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5:1696-1700.
15. Schaller G. Drug interaction of capecitabine and phenytoin in the therapy of cerebral and visceral metastatic breast cancer. Ann Oncol 2000; 11:12-39.
16. Copur MS, Ledakis P, Bolton M, Morse AK, Werner T, Norvell M, et al. An adverse interaction between warfarin and capecitabine: a case report and review of the literature. Clin Colorectal Cancer 2001; 1:182-184.
17. Shah HR, Ledbetter R, Diasio R, Saif MW. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer 2006; 5:354-358.
18. Camidge R, Reigner B, Cassidy J, Grange S, Abt M, Weidekamm E, et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 2005; 23:4719-4725.
19. Kanamitsu SI, lto K, Okuda H, Ogura K, Watabe T, Muro K, et al. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vivo data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil. Drug Metab Dispos 2000; 28:467-474.
20. Henning IM, Naik JD, Brown S, Szubert A, Anthoney DA, Jackson DP, et al. Severe sequence-specific toxicity when capecitabine is given after fluorouracil and leucovorin. J Clin Oncol 2008; 26:3411-3417.
21. Lonardi S, Bortolami A, Stefani M, Monfardini S. Oral anticancer drugs in the elderly: an overview. Drugs Aging 2007; 24:395-410.
22. Bajetta E, Procopio G, Celio L, Gattinoni L, Delia Torre S, Mariani L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23:2155-2161.
23. Tong DK, Cheng CW, Ching Chan S, Ngor Wong L, Chow LW. Phase II study of an 'all-oral' regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer-safety, efficacy and quality of life. Oncology 2005; 68:520-525.
24. Hess D, Koberle D, Thurlimann B, Pagani O, Schonenberger A, Mattmann S, et al. Capecitabine and vinorelbine as first-line treatment in elderly patients (≥ 65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology 2007; 73:228-237.
25. Muss HB, Berry DL, Cirrincione C, Theodoulou M, Mauer A, Cohen H, et al. Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: results of CALGB/CTSU 49907. J Clin Oncol 2008; 26 (Suppl):s507.
26. Sargent DJ, Goldberg RM, Jacobson SO, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345:1091 -1097.
27. Goldberg RM, Tabah-Fish I, Bleiberg H, de Gramont A, Tournigand C, Andre T, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24:4085-4091.
28. Minea L, Stanculeanu DL, Cringeanu A, Anghel RN. Capecitabine monotherapy for elderly patients with metastatic breast cancer. J Clin Oncol 2004; 22 (Suppl):s797.
29. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plusleucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292.
30. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, ef al. Capecitabine colorectal cancer study group first-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13:566-575.
31. Escudero P, Verge V, Feliu J, Sanz-Lacalle J, Lopez R, Gomez MJ, et al. A study of capecitabine in elderly patients as first line treatment in advanced or metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22:3114.
32. Braud A, Joly F, Rios M. Preservation of activities of daily living (ADL) in a phase-ll impact study of oral capecitabine and vinorelbine in the treatment of metastatic carcinomas in patients 70 and older: the GERICO- 01 Study by the French FNCLCC Group. J Clin Oncol 2004; 22 (Suppl):768.
33. Twelves C, Butts CA, Cassidy J, Conroy T, Braud F, Diaz-Rubio E, et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005; 5:101-107.
34. Ershler WB. Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data. Crit Rev Hematol Oncol 2006; 58:68-78.
35. Keefe D. Gastrointestinal mucositis: a new biological model. Support Care Cancer 2004; 12:6-9.
36. Saif MW, Katirtzoglu NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs 2008; 19:447-464.
37. Marse H, Van Cutsem E, Grothey A, Valverde S. Management of adverse events and other practical considerations in patients reciving capecitabine (Xeloda). Eur J Oncol Nurs 2004; 8:18-30.
38. Lee W, Lockhart C, Kim RB, Rothemberg ML. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005; 10:104-111.
39. Ezzledin H, Diasio R. DPD deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004; 4:181-189.
40. Van Kluiberg AB. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. Cancer Invest 2006; 24:215-217.
41. Bosch TM. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol 2008; 448:63-76.
42. Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 2006; 6:288-296.
43. Milano G, Etienne-Grimaldi MC, Mari M, Lassaile S, Formento JL, Francoual M, ef al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008; 66:88-95.
44. Saif MW, Juneja V, Black G, Thronton J, Johnson MR, Diasio RB. Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dyhydropyrimidine dehydrogenase: is there a pharmacologic explanation? Supp Cancer Ther 2007; 4:211 -218.
45. Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008; 14:8-13.
46. Becker K, Erckenbrecht JF, Haussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 57:475-484.
47. Sudhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004; 15:681-664.
48. Canale ML, Camerini A, Stroppa S, Porta RP, Caravelli P, Mariani M, et al. A case of acute myocardial infarction during 5-fluorouracil infusion. J Cardiovasc Med 2006; 7:835-837.
49. Walko CM, Undley C. Capecitabine: a review. Clin Ther 2005; 27:23-44.
50. Kosmas C, Kafetratos MS, Kopterides P, Syrios J, Skopelrtis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134:75-82.
51. Frickofen N, Beck FG, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13:797-801.
52. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006; 11:325-335.
53. Pierga JY, Fumoleau P, Brewer Y, Zelek L, Martin D, Turpin FL, et al. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 2004; 88:117-129.
54. Stockier M, Sourjina T, Grimson P, Gebski V, Byrne M, Harvey V, et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 2007; 25 (Suppl):s1031.
55. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecrtabine in paclrtaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-493.
56. O'Shaughnessy J, Miles D, Vuketja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel in combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
57. Leonard R, O'Shaughnessy J, Vukelja S, Gorbounova V, Chan-Navarro CA, Maraninchi D, et al. Detailed analysis of a randomized Phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006; 17:1379-1385.
58. Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 2004; 22:2321-2327.
59. Mrozek E, Ramaswamy B, Young D, Rhoades CA, Kendra K, Allen J, et al. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Clin Breast Cancer 2006; 7:141-145.
60. Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2006; 24:4384-4390.
61. Gick U, Rochlitz C, Mingrone W, Pestalozzi B, Rauch D, Ballabeni P, et al. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. Oncology 2006; 71:54-60.
62. Puglisi F, Cardellino GG, Crivellari D, Di Loreto C, Magri MD, Minisini AM, et al. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Ann Oncol 2008; 19:1541-1546.
63. Bangemann N, Kuhle A, Ebert A, Buhler H, Schaller G. Capecitabine combined with trastuzumab in the therapy of intensively pre-treated HER2-overexpressing metastatic breast cancer (MBC). Ann Oncol 2000; 11 (Suppl4):s143a.
64. Xu L, Song S, Zhu J, Luo R, Li L, Jiao S, et al. A phase II trial of trastuzumab (H) -(-capecitabine (X) as first-line treatment in patients (pts) with HER2-positrve metastatic breast cancer. J Clin Oncol 2006; 24 (Suppl):s10615.
65. Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007; 25:792-799.
66. Bartsch R, Wenzel C, Aftorjai G, Pluschnig U, Rudas M, Mader RM, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25:3853-3858.
67. IshidaT, Kiba T, Takeda M, Matsuyama K,Teramukai S, Masuda N, et al. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2-overexpressing metastatic breast cancers after failure of both anthracyclines and taxanes. J Clin Oncol 2008; 26 (Supp0:s1117.
68. Yamamoto D, Iwase S, KHamura K, Odagiri H, Yamamoto C, Nagumo Y. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol 2008; 61:509-514.
69. Osako T, ho Y, Takahashi S, Tokudome N, Iwase T, Hatake K, et al. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2008; 62:159-164.
70. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecrtabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799.
71. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-4106.
72. Twelves C, Wong A, Nowacki MP, Abt M, Burns H III, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352:2696-2704.
73. Twelves C, Boyer M, Findlay M, Cassidy J, Wertzel C, Barker C, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37:597-604.
74. Scheithauer W, McKendrick J, Begbie S, Borner M, Bums Wi, Burns HA, et al. On behalf of the X-ACT Study Group; oral capecitabine as an alternative to iv 5-fluorouracil-based adjuvant therapy for colon cancer; safety results of a randomized, phase III trial. Ann Oncol 2003; 14; 1735-1743.
75. Diaz-Rubio E. Tabernero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, et al. Phase III study of capecitabine plus oxaliplatin versus continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial. J Clin Oncol 2007; 25:4224-4230.
76. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, ef al. Capecitabine plus oxaliplatin versus 5-fluorouracil/leucovorin plus oxaliplatin; a randomized comparison in metastatic colorectal cancer. J Clin Oncol 2007; 25:4217-4223.
77. Bennouna J, Ducreux M, Hebbar M, Ychou M, Lledo G, Conroy T, et al. Preliminary efficacy findings from a randomized phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first line treatment for metastatic colorectal cancer (MCRC). Gastrointestinal Cancers Symposium 2007; 220:272.
78. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26:2006-2012.
79. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Conn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523-3529.
80. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; [Accessed 2008]
81. Mayer RJ Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2007; 25:4165-4167.
82. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients. J Clin Oncol 2007; 25:102-109.
83. Lueck H, Von Minckwitz G, Du Bois A, Schrader I, Huober J, Heilmann V, et al. Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized, multicentre phase III study of the AGO breast cancer study group. J Clin Oncol 2006; 24 (Suppl):s517.
84. Von Minckwitz G, Zielinski C, Maarteense E, Vogel P, Schmidt M, Eidtmann H, et al. Capecitabine v capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG26/BIG 3-05). J Clin Oncol 2008; 26 (Suppl):s1025.
85. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-2743.
86. Thomas ES, Gomez HL Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25:5210-5217.
87. Wardley A. Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer. Oncologist 2006;11 (Suppl 1):s20-s26.
88. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92:1759-1768.
89. O'Shaughnessy J, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, et al. Randomized, openlabel, phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/ metastatic breast cancer. Ann Oncol 2001; 12:1247-1254.
90. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86:1367-1372.
91. Fumoleau P, Largillier R, Clippe C, Dièras V, Orfeuvre H, Lesimple T, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40:536-542.
92. Reichaidt P, Von Minckwitz G, Thuss-Patience P, Jonat W, Kölbl H, Jänicke F, et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane containing therapy. Ann Oncol 2003; 14:1227-1233.
93. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I. Oral capecitabine in anthracycline- and taxane-pretreated advanced/ metastatic breast cancer. Acla Oncol 2004; 43:186-189.
94. Venturini M, Paridaens R, Ressner D, Vaslamatzis MM, Nortier JW, Salzberg M, et al. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with preheated advanced breas cancer. Oncology 2007; 72:51-57.
95. Andreetta C, Puppin C, Minisini AM, Valent F, Pegolo E, Damante G, et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol 2008; [Accessed 2 September 2008]
96. Osako T, Ito Y, Ushijima M, Takahashi S, Tokudome N, Sugihara T, et al. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 2008; [Accessed 2008]
97. Honda J, Sasa M, Moriya T, Bando Y, Hirose T, Takahashi M, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results. J Med Invest 2008; 55:54-60.
98. Puglisi F, Cardoso F, Lebrun F, Piccart M. First-line treatment of metastatic breast cancer: available evidence and current recommendations. Am J Cancer 2006; 5:99-110.
99. Johnson L, Cameron D, Barrett-Lee P, Canney P, Bliss JM. Improving adjuvant chemotherapy in breast cancer - can we get more for less with TACT2? Clin Oncol (R Coll Radiol) 2007; 19:593-595.
100. Maher JF, Villalona-Calero MA. Taxanes and capecitabine in combination: rationale and clinical results. Clin Breast Cancer 2002; 2:287-293.
101. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
102. Toi M, Bando H, Horiguchi S, Takada M, Kataoka A, Ueno T, et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. 8r J Cancer 2004; 90: 2338-2343.
103. Puglisi F, Andreetta C, Valent F, Minisini AM, Rijavec E, Russo S, et al. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anticancer Drugs 2007; 18:883-888.
104. Miles D, Vukelja S, Moiseyenko V, Cervantes G, Mauriac L, Van Hazel G, et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clin Breast Cancer 2004; 5:273-278.
105. Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Lluch A, et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Proc Am Soc Clin Oncol 2005; 23:581a.
106. Batista N, Perez-Manga G, Constenla M, Ruiz A, Carabantes F, Castellanos J, et al. Phase II study of capecitabine in combination with paclriaxe) in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer 2004; 90:1740-1746.
107. Ghosn M, Farhat F, Kattan J, Hanna C, Younes F, Haddad N, et al. Navcap (vinorelbine and capecitabine) versus navcap followed by weekly docetaxel as first-line treatment in metastatic breast cancer patients:a randomized multicenter phase II trial. J Clin Oncol 2008; 26 (Suppl):s1119.
108. Ghosn M, Kattan J, Farhat F, Younes F, Gasmi J. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Research 2006; 26:2451-2456.
109. Ghosn M, Kattan J, Farhat F, Younes F, Nasr F, Moukadem W, et al. Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long term-results of a pilot phase II trial. Cancer Chemother Pharmacol 2008; 62:11-18.
110. Tubiana-Mathieu N, Bougnoux P, Bequart D, Chan A, Majois F, Espie M, et al. An international phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2007; 25 (Suppl):s1056.
111. Andres R, Mayordomo Jl, Lara R, Lastra R, Prtega E, Polo E, et al. Gemcitabine/capecitabine in patients with metastatic breast cancer pretrseated with anthracyclines and taxanes. Clin Breast Cancer 2005; 6:158-162.
112. Ciruelos EM, Baselga J, Cortes-Funes H, Lluch A, Mayordomo Jl, Ojeda B, et al. Multicentric phase II trial of gemcitabine plus capecitabine combination in the treatment of previously anthracycline (An)-treated metastatic breast cancer (MBC): SOLTI 0301 Study. J Clin Oncol 2007; 25 (Suppl):s1051.
113. Lechleider RJ, Kaminskas E, Jiang X, Aziz R Bullock J, Kasiiwai R, et al. bcabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Clin Cancer Res 2008; 14:4378-4384.
114. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of iapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; [Accessed 11 January 2008]
115. DeUapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008; 26:4899-4905.
116. Vallbohmer D, Yang DY, Kuramochi H, Shimizu D, Oanenberg KD, Lindebjerg J, et al. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int J Oncol 2008; 31:413-418.
117. Twelves C, Scheithauer W, McKendrick J, Nowacki M, Seitz J, Van Hazel G, et al. Capecitabine versus 5-FU/LV in stage III colon cancer: updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. Gastrointestinal Cancers Symposium 2008; abstract 274.
118. Cornella P, Massidda B, Filippelli G, Farris A, Natale 0, Barberis G, et al. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology Study 0401. J Cancer Res Clin Oncol 2008; [Accessed 22 August 2008].
119. Carrato A, Gallego-Plazas J, Guillén-Ponce C. Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Expert Rev Anticancer Ther 2008; 8:161-174.
120. Punt CJ, Koopman M. Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer. J Clin Oncol 2008; 26:1907-1908.
121. Borner MM, Bemhard J, Dietrich D, Popescu R, Wernli M, Saletti P, et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005; 16:282-288.
122. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100:279-287.
123. Choi CK, Chan RT, Tung SY, Lui L, Ski S, Au GK, ef al. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma-a dual-centre phase II study: the MAC-6. Clin Oncol (R Coll Radiol) 2008; 20: 168-175.
124. Patt Y2, Lee FC, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol 2007; 30:350-357.
125. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24:4069-4077.
126. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779-4786.
127. Kohne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC Study 40015. Ann Oncol 2008; 19:920-926.
128. Heinemann V, Moosmann N, Vehling-Kaiser U, Stauch M, Oruzio D, Schulze M, et al. XELIRI plus cetuximab versus XELOX plus cetuximab for first-line therapy of metastatic colorectal cancer (CRC): a randomized trial of the AIO CRC Study Group 2007. Gastrointestinal Cancers Symposium 2007; abstract 278.
129. Liu G, Franssen E, Fitch Ml, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15:110-115.
130. Bomer MM, Schoffski P, De Wit R, Caponigro F, Cornelia G, Sulkes A, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38:349-358.
131. Twelves C, Gollins S, Grieve R, Samuel L A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/ leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17:239-245.